Manish Aghi, MD, PhD

Principal Investigator, Brain Tumor Research Center
Member, Helen Diller Family Comprehensive Cancer Center
Associate Professor
Department of Neurosurgery
aghim@neurosurg.ucsf.edu

Manish Aghi is a neurosurgeon and scientist at University of California, San Francisco (UCSF). He completed his MD-PhD degrees through the MSTP program at Harvard Medical School, followed by neurological surgery residency and postdoctoral training at Massachusetts General Hospital. He is currently faculty in the department of neurological surgery and graduate division of biomedical sciences, as well as a principal investigator in the Brain Tumor Research Center at UCSF. His clinical practice is focused on the surgical management of brain and skull base tumors, with special emphasis on intraoperative brain mapping for glioma surgery, pituitary tumor surgery, and minimally invasive endoscopic skull base surgery. Work in the Aghi laboratory has been funded by NIH and private foundations since 2008 and is focused on the role of tumor-microenvironment interactions in driving aggressive biology and therapeutic resistance in benign and malignant brain tumors like pituitary adenomas and gliomas. Active areas of research include the role of tumor-associated macrophages in glioblastoma growth, whole genome sequencing of pituitary adenomas, metabolic changes occurring after anti-angiogenic therapy in glioblastoma, and the role of a tyrosine kinase-integrin receptor complex in driving invasive resistance in glioblastoma. He serves as PI on multiple industry sponsored and investigator-initiated phase I-II clinical trials comparing immunotherapy versus anti-angiogenic theray of recurrent glioblastoma, as well as investigating convection-enhanced delivery of oncolytic viruses and nanoliposomal chemotherapy to recurrent glioblastoma.

Primary Thematic Area: 
Cancer Biology & Cell Signaling
Secondary Thematic Area: 
Vascular & Cardiac Biology
Research Summary: 
Defining the interaction between tumor cells and the microenvironment in glioblastoma, including during therapeutic resistance

Websites

Publications: 

Familial melanoma-astrocytoma syndrome: synchronous diffuse astrocytoma and pleomorphic xanthoastrocytoma in a patient with germline CDKN2A/B deletion and a significant family history.

Clinical neuropathology

Chan AK, Han SJ, Choy W, Beleford D, Aghi MK, Berger MS, Shieh JT, Bollen AW, Perry A, Phillips JJ, Butowski N, Solomon DA

GLUT3 upregulation promotes metabolic reprogramming associated with antiangiogenic therapy resistance.

JCI insight

Kuang R, Jahangiri A, Mascharak S, Nguyen A, Chandra A, Flanigan PM, Yagnik G, Wagner JR, De Lay M, Carrera D, Castro BA, Hayes J, Sidorov M, Garcia JL, Eriksson P, Ronen S, Phillips J, Molinaro A, Koliwad S, Aghi MK

Erratum to: Surgical resection of fourth ventricular ependymomas: case series and technical nuances.

Journal of neuro-oncology

Winkler EA, Birk H, Safaee M, Yue JK, Burke JF, Viner JA, Pekmezci M, Perry A, Aghi MK, Berger MS, McDermott MW

Single-cell sequencing maps gene expression to mutational phylogenies in PDGF- and EGF-driven gliomas.

Molecular systems biology

Müller S, Liu SJ, Di Lullo E, Malatesta M, Pollen AA, Nowakowski TJ, Kohanbash G, Aghi M, Kriegstein AR, Lim DA, Diaz A

Surgical resection of fourth ventricular ependymomas: case series and technical nuances.

Journal of neuro-oncology

Winkler EA, Birk H, Safaee M, Yue JK, Burke JF, Viner JA, Pekmezci M, Perry A, Aghi MK, Berger MS, McDermott MW